Clinical Trial Update: TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 trial of TC-5619 as augmentation therapy to improve cognition in outpatients with cognitive dysfunction in schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• TC-5619

Snippet

Sponsor: Targacept Inc. | Conditions: Cognitive Dysfunction, Schizophrenia | Phase 2 | Status: COMPLETED